BeiGene first out of the gate with $132m IPO

By GlobalCapital
20 Jan 2016

BeiGene is looking to raise $132m from a Nasdaq IPO, with the firm kicking off bookbuilding on Tuesday for what will be the year’s first listing of a Chinese issuer in the US.

The company, which makes cancer drugs, is marketing 5.5m American Depositary Shares at $22-$24 apiece. The trade comes with a 15% greenshoe of 825,000 ADS. Cowen & Co, Goldman Sachs and Morgan Stanley are the lead underwriters.

Two investors have signed up as anchors for the deal. Hillhouse ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial